- Home
- NCEL vs TXMD Comparison
NCEL vs TXMD Comparison
Compare NCEL & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCEL | TXMD |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | Switzerland | United States |
| Employees | 4 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 24.4M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | NCEL | TXMD |
|---|---|---|
| Price | $3.36 | $2.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 31.5K | 17.3K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $212.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $1.83 | $0.98 |
| 52 Week High | $5.12 | $2.95 |
Technical Indicators
Market Signals| Indicator | NCEL | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 52.22 | 56.46 |
| Support Level | $3.03 | $2.10 |
| Resistance Level | $3.54 | $2.29 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 55.71 | 80.83 |
Price Performance
Historical ComparisonAbout NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.